Targeted Sequencing And Resequencing Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Targeted sequencing and resequencing technologies focus on analyzing specific subsets of the genome rather than entire genomes, enabling cost-effective and high-throughput genomic analysis for research and clinical use. The market includes sequencing platforms, library preparation kits, bioinformatics software, and associated consumables. Applications span oncology, rare disease diagnosis, pharmacogenomics, and infectious disease surveillance.

• •Includes targeted gene panels, whole exome sequencing (WES), and targeted resequencing assays
• •Serves both research laboratories and clinical diagnostic laboratories worldwide
• •Integrates wet-lab reagents with computational analysis tools and data interpretation software

The market is fueled by the increasing adoption of next-generation sequencing in clinical settings, particularly for cancer diagnostics and hereditary disease screening. Pharmaceutical companies are leveraging resequencing technologies to accelerate drug discovery and biomarker identification. Government initiatives promoting precision medicine and the integration of genomics into routine healthcare further support market expansion.

• •Rising oncology applications driving demand for tumor profiling and liquid biopsy sequencing
• •Expanding use of pharmacogenomics to guide personalized drug therapy decisions
• •Favorable regulatory approvals for NGS-based companion diagnostics and in-vitro diagnostics

The market is segmented by product type, application area, end user, and geography. Product segments include sequencing systems, consumables, and bioinformatics solutions, while applications cover oncology, reproductive health, rare diseases, and other clinical indications. Regionally, North America leads due to strong healthcare infrastructure and high research spending, while Asia-Pacific is projected to grow the fastest driven by expanding biotech sectors in China, India, and Japan.

• •North America accounts for the largest share, supported by the FDA's supportive regulatory pathway for NGS diagnostics
• •Asia-Pacific is the fastest-growing region, propelled by government genomics programs and increasing clinical adoption
• •Europe holds a significant share with strong academic research activity and established clinical sequencing networks

What are the recent trends and outlook?

The market is witnessing a convergence of sequencing technologies with artificial intelligence and machine learning for more accurate variant interpretation and faster data analysis. Long-read sequencing is gaining traction for structural variant detection, while single-cell sequencing opens new research frontiers. Over the forecast period, the continued democratization of sequencing technology and its integration into routine clinical workflows are expected to sustain the market's robust growth trajectory.

• •Integration of NGS with liquid biopsy for non-invasive cancer screening and disease monitoring is accelerating
• •Advances in single-cell and spatial transcriptomics are creating new market opportunities
• •Cloud-based bioinformatics platforms are reducing the computational barrier for smaller laboratories to adopt sequencing technologies